Effects of CB1 receptor negative allosteric modulator Org27569 on oxycodone withdrawal symptoms in mice.

Abstract

Targeting cannabinoid receptor type 1 (CB1R) has shown promise for treating opioid withdrawal symptoms. This study aimed to investigate the efficacy of a specific CB1R negative allosteric modulator (NAM), Org27569, in reducing both naloxone-precipitated and protracted withdrawal symptoms in oxycodone-dependent mice. Mice received escalating doses of oxycodone (9-33mg/kg IP) or saline twice daily for 9 days, followed by a final dose of oxycodone (33mg/kg) or saline in the morning of day 9. In one cohort, the impact of Org27569 (3, 10, and 30mg/kg) on naloxone (10mg/kg IP) precipitated withdrawal symptoms was assessed. In another cohort, Org27569 (3mg/kg) effects on the acquisition of conditioned place aversion to naloxone (0.6mg/kg) precipitated opioid withdrawal, on behaviour following a 7-9-day abstinence period, and on naloxone (0.6mg/kg) precipitated withdrawal-induced escape behaviour in a novel assay were assessed. Although Org27569 decreased opioid withdrawal-induced jumping at doses of 10 and 30mg/kg, these effects were confounded by reduced locomotion. At all doses tested, Org27569 had a modest inhibitory effect on gastrointestinal motility. At the lower dose of 3mg/kg, which was not confounded by locomotor effects, Org27569 did not impact naloxone-precipitated withdrawal-induced jumping, acquisition of oxycodone withdrawal-induced conditioned place aversion, or naloxone-precipitated withdrawal-induced escape behaviour in a novel assay. A clear protracted opioid withdrawal phenotype was not observed in assays of anxiety-like or social behaviour. Org27569 effects on negative affective-like symptoms were confounded by locomotor effects and effects on gastrointestinal motility were not opioid withdrawal specific. Further studies are needed in a model that produces a more pronounced protracted withdrawal syndrome.